Related Experiment Video
Updated: Dec 24, 2025
05:33
Rapid Fabrication of Custom Microfluidic Devices for Research and Educational Applications
Published on: November 20, 2019
9.2K
Biomaterials and Microfluidics for Drug Discovery and Development
Mariana R Carvalho1,2,3, Roman Truckenmuller4, Rui Luís Reis1,2,3
13B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal.
Advances in Experimental Medicine and Biology
|April 15, 2020
Summary
Microfluidics and biomaterials create advanced 3D models that better mimic the body, improving drug discovery. These organ-on-a-chip systems enhance understanding of disease and drug development.
Area of Science:
- Biomedical Engineering
- Cell Biology
- Drug Discovery
Background:
- Microfluidic devices offer advanced in vitro models that mimic in vivo conditions for disease research.
- Integrating biomaterials with microfluidics enhances the simulation of cellular microenvironments, including 3D structure and nutrient perfusion.
- Microfluidics' miniaturization and high throughput capabilities are driving innovation in drug discovery and development.
Purpose of the Study:
- To provide an overview of recent advancements in microfluidics for drug discovery.
- To highlight the role of biomaterials in developing sophisticated 3D in vitro models.
- To emphasize the contribution of organ-on-a-chip technologies in preclinical research.
Main Methods:
- Review of recent literature on microfluidic applications in drug discovery.
- Analysis of biomaterial integration in 3D cell culture models.
- Evaluation of organ-on-a-chip technologies for mimicking physiological conditions.
Main Results:
- Microfluidics combined with biomaterials closely replicate the cellular microenvironment.
- Organ-on-a-chip technologies show significant promise for drug screening and disease modeling.
- These integrated systems accelerate the drug discovery and development pipeline.
Conclusions:
- Microfluidic devices and biomaterials are revolutionizing in vitro modeling for drug discovery.
- Organ-on-a-chip technology represents a significant advancement in preclinical drug evaluation.
- The synergy between microfluidics and biomaterials facilitates more accurate prediction of drug efficacy and toxicity.
